Ultragenyx Pharmaceutical Inc. (0LIF.L)

42,76 -2,01 (-4,48%) Alla chiusura: 06:29PM BST

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 1.276

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Emil D. Kakkis M.D., Ph.D.	Founder, President, CEO & Director	1,46M	1,27M	1960
Mr. John Richard Pinion II	Chief Quality Operations Officer & Executive VP of Translational Sciences	860,05k	N/D	1966
Mr. Erik Harris	Executive VP & Chief Commercial Officer	878,77k	N/D	1971
Mr. Howard Horn	Executive VP of Corporate Strategy & CFO	184,81k	N/D	1978
Mr. Theodore A. Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer	N/D	N/D	1971

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Governance aziendale

L'ISS Governance QualityScore di Ultragenyx Pharmaceutical Inc. al 29 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 1; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.